Table 1 Published condition-specific preference-based instruments
Condition | Instrument [references] | Dimensions | Number of health states | Method of eliciting utilities | Groups for utility elicitation | Scaling anchors | Country |
|---|---|---|---|---|---|---|---|
Aberrant behaviour | Aberrant Behavior Checklist -Utility Index (ABC-UI) | 7 | 3^(7) = 2,187 | TTO (LT-TTO worse than dead) | UK general public | Best(1), worst (0) | UK |
Asthma | Asthma Quality of Life Questionnaire- 5 Dimensions (AQL-5D) | 5 | 5^(5) = 3,125 | TTO | UK general public | Best (1), worst (0) | UK |
Bladder problems | Incontinence Utility Index (IUI) | 5 | 3^(5) = 243 | TTO | UK general public | Perfect health (1), dead (0) | UK Spain |
Bladder problems | Overactive Bladder Questionnaire- 5 Dimensions (OAB-5D) | 5 | 5^(5) = 3,125 | TTO | UK general public | Full health (1), dead (0) | UK USA |
Cancer | European Organisation for Research and Treatment in Cancer Core Quality of Life Questionnaire – 8 Dimensions (EORTC-8D) [7, 45,46,47,48] | 8 | 81,920 | TTO | UK general public Sri Lankan general public | Best (1), worst (0) | UK Sri Lanka |
Cancer | European Organisation for Research and Treatment in Cancer Core Quality of Life Questionnaire – 10 Dimensions QLU-C10D | 10 | 4^(10) = 1,048,576 | DCE-TTO (Australia, France, Austria, Italy, and Poland) DCE (Canada, Netherlands, Germany, UK, U.S.) | General public | Best (1), worst (0) | Australia Netherlands Canada France Germany UK USA Austria, Italy, and Poland |
Cancer | European Organisation for Research and Treatment in Cancer Core Quality of Life Questionnaire – Preference-Based Measure (QLQ-PBM) [61] | 8 | 105 | TTO | Dutch general public | Best (1),worst (-1) -1 to 0 worse than dead | Netherlands |
Cancer | Functional Assessment of Cancer Therapy – 8 Dimensions (FACT-8D) | 8 | 1744 participants; 16 choice pairs; 256 observations per choice set | DCE | Patients with common cancers | Best (1), worst (0) | Australia |
Cancer (breast) | Breast Utility Instrument (BUI) | 10 | N/A | N/A | N/A No. utilities were elicited yet, so patients with breast cancer is an error. | N/A | Canada |
Cerebral palsy | Cerebral Palsy-6 Dimensions | 6 | 5^(6) = 15,625 | DCE-TTO | Australian general public | Best (1), worst (0) | Australia |
Cystic fibrosis | Cystic Fibrosis Questionnaire-Revised-8 Dimensions (CFQ-R-8 D) [69] | 8 | 3^(8) = 6,561 | TTO | UK general public | Best (1), worse than dead (< 0) | UK |
Dementia | Dementia Quality of Life-Utility (patient self-report and carer proxy-report) DEMQOL-U | 5 4 | 4^(5) = 1,024 4^(4) = 256 | TTO | UK general public and patients UK general public and carers | Best (1), worst (0) | UK |
Dementia | Alzheimer’s Disease-5 Dimensions | 5 | 4^(5) = 1,024 | DCE-TTO BWS | Australian general public and patients with dementia & carer dyads | Best (1), worst (0) | Australia |
Diabetes | 5 | 4^(5) = 1024 | VAS SG | People with type 1 or 2 diabetes | Best (1), worst (0) | USA | |
Diabetes | Diabetes Health Profile-3 Dimensions and 5-Dimensions (DHP-3D and DHP-5D) [80] | 3 5 | 33 were valued | TTO | UK general public | Best (1), worst (0) | UK |
Diabetes | Health and Self-Management in Diabetes Questionnaire (HASMID) (HASMID-8 HASMID-10) | 8 10 | 262,144 profiles 120 choice sets across 10 survey versions | DCE-TTO | UK general public and Individuals with diabetes | Unanchored and WTP estimates | UK |
Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy Quality of Life-8 Dimensions (DMD-QoL-8D) [83] | 8 | 4^(8) = 65,536 | DCE-TTO | UK general public | Best (1), dead (0) | UK |
Epilepsy | Epilepsy-specific Quality of Life – 6 Dimensions (NEWQOL-6D) | 6 | 4^(6) = 4,096 | TTO | UK general public People with epilepsy | Best (1), worst (0) | UK |
Heart disease | MacNew Heart Disease Health-Related Quality of Life Instrument -7 Dimensions (MacNew) [87] | 7 | 4^(7) = 16,384 | N/A | N/A | N/A | Australia |
Human immunodeficiency virus (HIV) | Preference-based HIV index (PB-HIV) | 7 | 3^(7) = 2,187 | EQ-VAS | People with HIV | Best (100), and worst (0) | Canada |
Mental health | Clinical Outcomes in Routine Evaluation-Outcome Measure – 6 Dimensions | 6 | 33 plausible health states (Rasch vignette approach) 3^(6) = 729 CORE-6D health states | TTO | UK general public | Full health (1), dead (0) | UK |
Mental health | Recovering Quality of Life Utility Index (ReQoL-UI) | 7 | 66 health states valued Each participant valued 8 health states | TTO Lead-time TTO (states worse than dead) | Nationally representative sample from Scotland, England, Wales | Best (1), worst (0) | UK |
Mobility | Mobility Quality of Life-7 Dimensions (MobQoL-7D) | 7 | 4^(7) = 16,384 | VAS | UK general public Representative sample of people with impaired mobility | Best (100), worst (0) | UK |
Multiple sclerosis | Multiple Sclerosis Impact Scale – 8 Dimensions, and -8 Dimensions patient versions (MSIS-8D MSIS-8D-P) | 8 | 4^(8) = 65,536 | TTO | UK general public People with MS | Best (1), worst (0) | UK |
Multiple sclerosis | Multiple Sclerosis Impact Scale – Preference-Based Measure (MSIS-PBM) [61] | 6 | 100 | TTO | Dutch general public | Best (1), worst (-1) -1 to 0 worse than dead | Netherlands |
Multiple sclerosis | Health-related quality of life in people with neurological conditions | 6 | 59 health states 47 single-attribute states 6 corner states 3 marker states: worst, best, dead | SG | General public sample, and patients with MS | Best (1), worst (0) | UK |
Multiple sclerosis | Preference-Based Multiple Sclerosis Index (P-PBMSI) | 5 | 3^(5) = 243 | SG RS | People with MS | Best (1), worst (0) | Canada |
Myelofibrosis | Myelofibrosis-8 Dimensions (MF-8D) [107] | 8 | 2560 | TTO | UK general public | Best (1), worst (0) | UK |
Obesity | Weight-specific Adolescent Instrument for Economic-Evaluation (WAITe) [108,109,110] | 5 | 7^(5) = 16,807 | TTO | UK general public | Best (1), worst (0) | UK |
Obesity | Preference-Based Index of Weight-Related Quality of Life (PBI-WRQL) [111] | 7 | 3^(7) = 2,187 | EQ-VAS | Patients | Best (100), worst (0) | Canada |
Oral health | Caries Impacts and Experiences Questionnaire for Children Utility version (CARIES-QC-U) | 4 | 3^(5) = 243 | DCE-TTO BWS | Adolescents and adults from the general public | Best (1), worst (0) | UK |
Oral health | Early Childhood Oral Health Impact Scale-4 Dimensions (ECOHIS-4D) [114, 115] | 4 | 3^(4) = 81 | DCE-TTO | Australian general public | Best (1), worst (0) | Australia |
Palliative care | Palliative Care Outcome Scale Descriptive System (POS-E) [116] | 3 | 3^(7) = 2187 | N/A | N/A | N/A | UK |
Rheumatoid arthritis | Multiattribute Health Outcome Measure for Rheumatoid Arthritis (MHOM RA) [117] | 6 | 4^(6) = 40,096 | TTO (general health preference) | Patients with rheumatoid arthritis | Best (1), worst (0) | UK |
Rheumatoid arthritis | Health Assessment Questionnaire – Preference-Based Measure (HAQ-PBM) [61] | 5 | 56 | TTO | Dutch general public | Best (1), worst (0) | Netherlands |
Vision | Vision Quality of Life Index | 6 | 5^(6) = 15,625 | TTO and RS (intermediate item responses) | Patients with visual impairment (Canada) Patients with diabetic retinopathy, diabetic macular edema, and keratoconus (Australia) Patients with visual impairment (India) | Best (1), dead (0), States worse than dead -0.25 | Canada Australia India |
Vision | Visual Function Questionnaire – Utility Index (VFQ-UI) | 6 | 5^(6) = 15,625 | TTO | General public from Australia, Canada, UK, USA | Best (1), worst (0) | Australia, Canada, UK, USA |